Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

AMGEN-BIO-FARMACÊUTICA LDA

NIF 502942959
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €6,810,485 95 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €6,810,485 95 contracts
A2 · Late Publication €12,359,793,104 2,271 contracts
Contract published to BASE more than 10 days after the signing date
LOW €12,359,793,104 2,271 contracts
A5 · Threshold Splitting €4,650,844 77 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €4,650,844 77 contracts
A6 · Low Competition €8,043,999 37 contracts
Only one bidder participated in a competitive procedure
MEDIUM €8,043,999 37 contracts
A9 · Abnormal Price Reduction €15,515,999,528 851 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €15,515,999,528 851 contracts
C3 · Missing Mandatory Fields €10,460,671 76 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,460,671 76 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

358
€1,603,092,759
75
€649,732,417
290
€580,332,748
27
€573,532,310
286
€570,507,473
82
€563,217,941
42
€562,668,158
163
€557,971,463
34
€557,785,137
37
€539,877,495
234
€527,994,233
19
€508,855,787
20
€494,443,575
36
€487,664,043
179
€486,052,867
19
€482,704,476
84
€477,595,570
61
€475,913,005
17
€466,732,413
21
€461,650,024
Page 1 of 3 · 54 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 37 contracts

BEAD20250152 - AQUISIÇÃO DE IMUNOMODULADORES - ECULIZUMAB
PT · 11300361 · Ao abrigo de acordo-qu...
A6 · Low Competition
€349,440 2025-03-21
CITOTOXICOS- CARFILZOMIB - 1ºSEMESTRE
PT · 11238745 · Ao abrigo de acordo-qu...
A6 · Low Competition
€297,128 2025-02-20
SOTORASIB 120 MG COMP
PT · 11197342 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€419,976 2025-01-15
Aquisição de Eculizumab 300 mg Sol inj Fr 30 ml IV ao Abrigo do AQ 2023/491
PT · 11145642 · Ao abrigo de acordo-qu...
A6 · Low Competition
€412,160 2025-01-09
C/ BASE NO CPA 2023_491
PT · 11177263 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€156,800 2024-12-30
Aquisição do medicamento - Bevacizumab
PT · 11203386 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€76,800 2024-12-23
Aquisição de DARBEPOETINA ALFA 100 ¿G/0.5 ML SOL INJ SER 0.5 ML IV SC (AQ2023307)
PT · 11091831 · Ao abrigo de acordo-qu...
A6 · Low Competition
€14,100 2024-12-12
Aquisição de ADALImumab 40 mg/0.8 ml Sol inj Caneta 0.8 ml SC - Amgen
PT · 11067792 · Ajuste Direto Regime G...
A6 · Low Competition
€37,200 2024-12-05
DARBEPOETINAS ALFA
PT · 11050170 · Ao abrigo de acordo-qu...
A6 · Low Competition
€78,840 2024-11-27
EVOLOCUMAB 140 MG/1 ML SOL INJ CANETA 1 ML SC
PT · 11059206 · Ajuste Direto Regime G...
A6 · Low Competition
€1,414 2024-11-26
ADALIMUMAB 40 MG/0.4 ML SOL INJ CANETA 0.4 ML SC
PT · 11030189 · Ajuste Direto Regime G...
A6 · Low Competition
€216,000 2024-11-12
CITOTOXICOS - CARFILZOMIB
PT · 11015344 · Ao abrigo de acordo-qu...
A6 · Low Competition
€162,070 2024-11-08
IMUNOMODULADORES - BLINATUMOMAB
PT · 10935140 · Ao abrigo de acordo-qu...
A6 · Low Competition
€58,282 2024-09-24
BEAD20240445 - AQUISIÇÃO DE CITOTÓXICOS (OUTROS) - CARFILZOMIB - 3 MESES
PT · 10898308 · Ao abrigo de acordo-qu...
A6 · Low Competition
€108,046 2024-09-02
AQUISIÇÃO DE MEDICAMENTOS PARA AS NECESSIDADES IMEDIATAS DOS DOENTES-DESPACHO 1571-B/2016
PT · 10961650 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€432,187 2024-08-08
Aquisição de Sotorasib 120 mg Comp
PT · 11038655 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€88,416 2024-07-11
BEAD20240334 - AQUISIÇÃO IMUNOMODULADORES - PANITUMUMAB
PT · 10795405 · Ao abrigo de acordo-qu...
A6 · Low Competition
€29,821 2024-06-27
BEAD20240274 - AQUISIÇÃO DE IMUNOMODULADORES - BLINATUMOMAB
PT · 10735997 · Ao abrigo de acordo-qu...
A6 · Low Competition
€116,565 2024-05-24
IMUNOMODULADORES
PT · 10726572 · Ao abrigo de acordo-qu...
A6 · Low Competition
€49,956 2024-05-20
IMUNOMODULADORES - PANITUMUMAB - 1º SEMESTRE
PT · 10698636 · Ao abrigo de acordo-qu...
A6 · Low Competition
€132,977 2024-05-03
IMUNOMODULADORES - BLINATUMOMAB
PT · 10690605 · Ao abrigo de acordo-qu...
A6 · Low Competition
€58,282 2024-04-29
41016724 - APREMILASTE 30 MG COMP
PT · 11219308 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€10,660 2024-04-03
DARBEPOETINA ALFA (VÁRIAS DOSAGENS)
PT · 10645686 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction A6 · Low Competition
€2,682,180 2024-04-02
ICP20240016- ECULIZUMAB
PT · 10668975 · Concurso público
A2 · Late Publication A6 · Low Competition
€349,440 2024-03-26
2024001531 – Aquisição de medicamentos
PT · 10631132 · Ajuste Direto Regime G...
A6 · Low Competition
€13,200 2024-03-22
UI/1232/2024 -ECULIZUMAB 300MG INJ- MUITO URGENTE
PT · 11363112 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€26,800 2024-03-20
Fornecimento de substância ativa: Sotorasib 120mg
PT · 10606747 · Ajuste Direto Regime G...
A6 · Low Competition
€265,248 2024-03-11
2024001120 – Aquisição de medicamentos
PT · 10673550 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€189,000 2024-03-06
BEVACIZUMAB 25 MG/ML SOL INJ FR V
PT · 10981346 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€493,411 2024-03-04
241G000340 - 2024 - Bevacizumab 25 mg/ml sol inj biossimilar fr
PT · 10596583 · Ajuste Direto Regime G...
A6 · Low Competition
€24,836 2024-03-04
Aquisição de ADALImumab 40 mg/0.8 ml Sol inj Caneta 0.8 ml SC – Amgevita
PT · 10590507 · Ajuste Direto Regime G...
A6 · Low Competition
€167,200 2024-02-27
Aquisição de BEVACIZUMAB BIO ao Lab. Amgen para a ULSASI para o ano de 2024
PT · 10575968 · Ajuste Direto Regime G...
A6 · Low Competition
€15,894 2024-02-22
241G000301 - SOTORASIB 120 MG COMP REV
PT · 10570666 · Ajuste Direto Regime G...
A6 · Low Competition
€22,104 2024-02-20
EX/847/2024 – SOTORASIB 120MG
PT · 10884617 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€294,720 2024-02-16
Adalimumab 20 mg/0,4 ml sol inj biossimi
PT · 10551418 · Ajuste Direto Regime G...
A6 · Low Competition
€562 2024-02-09
AQUISIÇÃO DO MEDICAMENTO SOTORASIB 120 MG DE FORNECIMENTO EXCLUSIVO DO LABORATÓRIO AMGEN - BIOFARMACÊUTICA
PT · 10554125 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€95,784 2024-02-05
Estimulantes da Eritropoiese
PT · 10441479 · Ao abrigo de acordo-qu...
A6 · Low Competition
€96,500 2024-01-02
Overview
Total Value Won
€15,678,365,307
Contracts Won
3,288
Score 109055 · CRITICAL RISK
NIF
502942959
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.I. [P-8cde]
    Gerente
    since 2014-08-19
  • J.M. [P-2b80]
    Gerente
    since 2011-12-15
  • M.F. [P-d8ab]
    Gerente
    since 2014-02-19
  • M.A. [P-c5e7]
    Gerente
    since 2010-10-12
  • P.F. [P-8896]
    Gerente
    since 2023-05-30
  • R.K. [P-36e2]
    Gerente
    since 2009-03-20
  • T.J. [P-d7ae]
    Gerente
    since 2009-03-20
  • T.G. [P-8f1f]
    Gerente
    since 2019-04-02
  • A.S. [P-e73b]
    Gerente
    2020-11-26 → 2023-05-30
  • A.H. [P-655e]
    Gerente
    2013-11-04 → 2014-02-19
  • C.I. [P-8cde]
    Gerente
    2015-07-23 → 2017-11-08
  • F.C. [P-6013]
    Gerente
    2012-11-27 → 2014-08-19
  • J.J. [P-2047]
    Gerente
    2009-10-30 → 2010-10-12
  • J.G. [P-cafe]
    Gerente
    2017-11-08 → 2020-11-26
  • M.F. [P-d8ab]
    Gerente
    2015-07-23 → 2025-04-14
  • M.A. [P-c5e7]
    Gerente
    2012-11-27 → 2013-11-04
  • O.M. [P-bcaa]
    Gerente
    2010-10-12 → 2011-12-15
  • R.P. [P-fb9d]
    Gerente
    2013-11-04 → 2014-08-19
  • R.W. [P-c2d8]
    Gerente
    2012-11-27 → 2013-11-04
  • R.D. [P-4892]
    Gerente
    2009-03-20 → 2009-10-30
  • T.J. [P-d7ae]
    Gerente
    until 2010-10-12
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned